Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of four combined MenABCWY vaccine formulations in adolescents
2014-005160-15Phase 2
- Sponsor
- Novartis
- Start
- Dec 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of meningococcal group A, B, C, W and Y vaccine and rMenB + OMV + MenACWY vaccine in meningococcal disease (4 arms), sponsored by Novartis. Primary endpoint: MenACWY seroresponse after vaccination.
02
Drugs
meningococcal group A, B, C, W and Y vaccinerMenB + OMV + MenACWY vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2014-005160-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005160-15.